ConductScience.org, home

Paper32676151

2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry.

Azzali E and 8 others. ACS Med Chem Lett, 2020. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. 2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. Papers, record 32676151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32676151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry.
PubMed
Journal
ACS Med Chem Lett
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.07
iCite
Revised in PubMed
2021-07-10
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Azzali EElisa
2Girardini MMiriam
3Annunziato GGiannamaria
4Pavone MMarialaura
5Vacondio FFederica
6Mori GGiorgia
7Pasca MRMaria Rosalia
8Costantino GGabriele
9Pieroni MMarco

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128749666Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.J Med Chem2017https://conductscience.org/library/papers/28749666PubMed
211848856Bioisosterism: A Rational Approach in Drug Design.Chem Rev1996https://conductscience.org/library/papers/11848856PubMed
311745742High throughput physicochemical profiling for drug discovery.J Pharm Sci2001https://conductscience.org/library/papers/11745742PubMed
422394197Palladium-catalyzed N-arylation of 2-aminothiazoles.Org Lett2012https://conductscience.org/library/papers/22394197PubMed
528605135Mechanistic Insight Leads to a Ligand Which Facilitates the Palladium-Catalyzed Formation of 2-(Hetero)Arylaminooxazoles and 4-(Hetero)Arylaminothiazoles.Angew Chem Int Ed Engl2017https://conductscience.org/library/papers/28605135PubMed
628344011The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.Lancet Respir Med2017https://conductscience.org/library/papers/28344011PubMed
731766441Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review.Int J Mol Sci2019https://conductscience.org/library/papers/31766441PubMed
820131845New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.J Med Chem2010https://conductscience.org/library/papers/20131845PubMed
930259757Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics.Future Microbiol2018https://conductscience.org/library/papers/30259757PubMed
1025559643Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.J Med Chem2015https://conductscience.org/library/papers/25559643PubMed
1124333612Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.Eur J Med Chem2014https://conductscience.org/library/papers/24333612PubMed
1222784641Ultrasound and deep eutectic solvent (DES): a novel blend of techniques for rapid and energy efficient synthesis of oxazoles.Ultrason Sonochem2013https://conductscience.org/library/papers/22784641PubMed
1329202222Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations.ACS Chem Biol2018https://conductscience.org/library/papers/29202222PubMed
1410534321Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.Drug Metab Dispos1999https://conductscience.org/library/papers/10534321PubMed
1517868596First tuberculosis cases in Italy resistant to all tested drugs.Euro Surveill2007https://conductscience.org/library/papers/17868596PubMed
1626071857Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.Eur J Med Chem2015https://conductscience.org/library/papers/26071857PubMed
1730144650The present state of the tuberculosis drug development pipeline.Curr Opin Pharmacol2018https://conductscience.org/library/papers/30144650PubMed
1826197353Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.J Med Chem2015https://conductscience.org/library/papers/26197353PubMed
1932353943Antibacterial Discovery: 21st Century Challenges.Antibiotics (Basel)2020https://conductscience.org/library/papers/32353943PubMed
2029529363Breaking the Base Barrier: An Electron-Deficient Palladium Catalyst Enables the Use of a Common Soluble Base in C-N Coupling.J Am Chem Soc2018https://conductscience.org/library/papers/29529363PubMed

Download CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
428992172-Aminooxazoles and 2-aminothiazoles: green regioselective synthesis and bioactivity.RSC Adv2026https://conductscience.org/library/papers/42899217PubMed
40971029A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.Med Microbiol Immunol2025https://conductscience.org/library/papers/40971029PubMed
40806215Therapeutic Potential of Isoxazole-(Iso)oxazole Hybrids: Three Decades of Research.Int J Mol Sci2025https://conductscience.org/library/papers/40806215PubMed
40649348Azirinyl-Substituted Nitrile Oxides: Generation and Use in the Synthesis of Isoxazole Containing Heterocyclic Hybrids.Molecules2025https://conductscience.org/library/papers/40649348PubMed
38415251Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Front Immunol2024https://conductscience.org/library/papers/38415251PubMed
36399878Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization.Eur J Med Chem2023https://conductscience.org/library/papers/36399878PubMed
35631406Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35631406PubMed
33672408Discovery of Substituted (2-Aminooxazol-4-yl)Isoxazole-3-carboxylic Acids as Inhibitors of Bacterial Serine Acetyltransferase in the Quest for Novel Potential Antibacterial Adjuvants.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/33672408PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32676151

GET https://conductscience.org/api/papers/v1/32676151/authors